Patients with this genetic variant are more likely to experience adverse drug reactions or failure of treatment.
Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.
ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.
Ligand Pharmaceuticals has agreed to buy the struggling Metabasis Therapeutics for $3.2 million in cash.
Scientists are calling Plexxikon’s experimental skin cancer drug a “breakthrough” after it successfully shrank tumors in clinical trial patients.
The company announced that it has enrolled the first two patients in a clinical trial evaluating nimotuzumab in patients with brain tumors from non-small cell lung cancer (NSCLC).